Related Experiment Videos
mTOR--beyond transplantation
Deborah A Young1, Cheryl L Nickerson-Nutter
1Wyeth Research, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, USA. dyoung@wyeth.com
Current Opinion in Pharmacology
|June 16, 2005
Summary
Blocking the mTOR pathway with rapamycin halts cell cycle progression. New molecules in this pathway offer therapeutic targets, and understanding rapamycin-independent activation may benefit autoimmune diseases.
Area of Science:
- Cell biology
- Immunology
- Pharmacology
Background:
- The mechanistic target of rapamycin (mTOR) kinase is crucial for activating various cell types.
- Rapamycin, an mTOR inhibitor, causes cell cycle arrest at the G1 phase.
- Recent discoveries have identified new molecules within the mTOR pathway.
Purpose of the Study:
- To explore novel therapeutic strategies by targeting the mTOR pathway.
- To investigate conditions and cell types where activation occurs independently of mTOR, even with rapamycin present.
- To assess the potential benefits of selective cell activation inhibition for autoimmune and inflammatory diseases.
Main Methods:
- Review of recent molecular discoveries in the mTOR pathway.
- Analysis of cell cycle regulation mechanisms.
- Examination of rapamycin's effects on different cell types under specific conditions.
Main Results:
- The mTOR pathway presents multiple targets for therapeutic intervention.
- Cellular activation can proceed independently of mTOR in certain contexts, even when rapamycin is administered.
- Selective inhibition strategies may be viable.
Conclusions:
- Targeting the mTOR pathway offers potential for developing new therapeutic agents.
- Understanding rapamycin-resistant activation is key for precise therapeutic application.
- Selective inhibition of cell activation could be beneficial for treating autoimmune and inflammatory conditions.